Monographie - Scopolamine N-butyl bromide

Última actualización :
08/05/2024

Scopolamine N-butyl bromide

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Buscapina	España
Buscolysin	Polonia
Buscopan	Alemania, Australia, Austria, Bélgica, Brasil, Canadá, Egipto, Emiratos Árabes Unidos, Finlandia, Islandia, Luxemburgo, Noruega, Nueva Zelanda, Países Bajos, Portugal, Suecia, Suiza, Túnez, Turquía
Butilbromuro de hioscina	Argentina, Colombia
Cifespasmo	Argentina
Colobolina	Argentina
Dolopina	Ecuador
Escopolamina N butyl bromuro	Chile
Hiocin	Venezuela
Hioscina	Argentina, Colombia, Marruecos
Hioscina butil bromuro	Colombia, Marruecos
Hyocidic	Irán
Hyoscine	Australia
Hyoscine hydrobromide	Canadá
Hyotex	Irán
Pasmodina Drawer	Argentina
Rupe N	Argentina
Scoburen	Francia
Selpirans	Venezuela
Spasmopan	Túnez
Xemol	Turquía

Bibliografía : Scopolamine N-butyl bromide

	Tipo	Publicación
1230	Periódico	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Periódico	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Periódico	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1757	Periódico	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1847	Periódico	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966	Periódico	Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer 2005 ; 13, 4: 239-245.
1970	Periódico	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Periódico	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
2055	Periódico	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2125	Periódico	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2176	Periódico	Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007 ; 15: 57-62.
2900	Periódico	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Periódico	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
4404	Póster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019

Mentions Légales